Page last updated: 2024-11-05

3-phenylbutyric acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

3-Phenylbutyric acid, also known as phenylbutyrate, is a short-chain fatty acid with potential therapeutic applications. It is primarily studied for its ability to reduce the levels of ammonia in the blood, making it a potential treatment for hepatic encephalopathy, a brain dysfunction associated with liver failure. The compound can be synthesized through various methods, including the Friedel-Crafts acylation of benzene with butyryl chloride followed by hydrolysis. 3-Phenylbutyric acid is typically administered orally and is known to exert its effects by promoting the conversion of ammonia into glutamine, a less toxic compound that can be excreted in the urine. Its mechanism of action also involves the modulation of gene expression related to glutamine synthetase, the enzyme responsible for ammonia detoxification. Research into 3-Phenylbutyric acid continues to explore its potential benefits in various medical conditions, including urea cycle disorders, hyperammonemia, and even cancer. It is also being investigated for its role in neuroprotection and its potential as an anti-inflammatory agent.'

3-phenylbutyric acid : A monocarboxylic acid that is butanoic acid substituted by a phenyl group at position 3. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID20724
CHEMBL ID2205242
CHEBI ID166657
SCHEMBL ID237091
MeSH IDM0110026

Synonyms (69)

Synonym
3-phenylbutyrate
3-phenylbutanoate
beta-methylhydrocinnamic acid
CHEBI:166657
beta-methylbenzenepropanoic acid
4593-90-2
nsc-177801
nsc177801
3-phenylbutyric acid
.beta.-phenyl-n-butyric acid
ENAMINE_005505
NCIOPEN2_000158
inchi=1/c10h12o2/c1-8(7-10(11)12)9-5-3-2-4-6-9/h2-6,8h,7h2,1h3,(h,11,12
772-17-8
nsc67346
nsc-67346
beta-phenylbutyric acid
3-phenylbutanoic acid
3-phenylbutyric acid, 98%
HMS1409K05
AKOS000120792
3-phenyl-butyric acid
CHEMBL2205242
3-phenylbutiric acid
A826934
benzenepropanoic acid, beta-methyl-
ai3-11112
nsc 177801
einecs 224-987-4
FT-0616339
SCHEMBL237091
AKOS016051249
3-phenylbutanoic acid #
benzenepropanoic acid, .beta.-methyl-
FT-0696619
FT-0696620
mfcd00002725
F0001-1246
(+/-)-3-phenylbutyric acid, purum, >=97.0% (gc)
b-phenylbutyrate
b-phenyl-n-butyrate
b-methylhydrocinnamate
beta-methylhydrocinnamate
beta-phenyl-n-butyrate
b-phenyl-n-butyric acid
beta-methylbenzenepropanoate
b-methylhydrocinnamic acid
(rs)-3-phenylbutanoate
beta-phenylbutyrate
(rs)-3-phenylbutanoic acid
b-methylbenzenepropanoic acid
b-phenylbutyric acid
beta-phenyl-n-butyric acid
b-methylbenzenepropanoate
CS-W017905
DTXSID10863421
mfcd00077842
SY231348
SY226436
(+/-)-3-phenylbutyric acid
EN300-17257
D77816
AS-57521
HY-W017189
SB47144
3-phenylbutanoicacid
SY109441
Z56899204
PD164991
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
antibacterial agentA substance (or active part thereof) that kills or slows the growth of bacteria.
bacterial xenobiotic metaboliteAny bacterial metabolite produced by metabolism of a xenobiotic compound in bacteria.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
benzenesAny benzenoid aromatic compound consisting of the benzene skeleton and its substituted derivatives.
monocarboxylic acidAn oxoacid containing a single carboxy group.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (5)

Assay IDTitleYearJournalArticle
AID715776Pro-oxidant activity in 0.1 M potassium phosphate buffer at pH 7.4 assessed as increase of oxidation potential by cyclic voltammetry analysis2012Bioorganic & medicinal chemistry, Sep-15, Volume: 20, Issue:18
Structure-anti-leukemic activity relationship study of ortho-dihydroxycoumarins in U-937 cells: key role of the δ-lactone ring in determining differentiation-inducing potency and selective pro-apoptotic action.
AID715802Cytotoxicity against human U937 cells after 48 hrs by trypan blue assay2012Bioorganic & medicinal chemistry, Sep-15, Volume: 20, Issue:18
Structure-anti-leukemic activity relationship study of ortho-dihydroxycoumarins in U-937 cells: key role of the δ-lactone ring in determining differentiation-inducing potency and selective pro-apoptotic action.
AID715803Antiproliferative activity against human U937 cells assessed as incorporation of [3H]-methyl-thymidine after 12 hrs by scintillation counting2012Bioorganic & medicinal chemistry, Sep-15, Volume: 20, Issue:18
Structure-anti-leukemic activity relationship study of ortho-dihydroxycoumarins in U-937 cells: key role of the δ-lactone ring in determining differentiation-inducing potency and selective pro-apoptotic action.
AID715795Induction of apoptosis in human U937 cells assessed as reduction of normal cells at 500 uM after 24 hrs by Annexin V-FITC double staining2012Bioorganic & medicinal chemistry, Sep-15, Volume: 20, Issue:18
Structure-anti-leukemic activity relationship study of ortho-dihydroxycoumarins in U-937 cells: key role of the δ-lactone ring in determining differentiation-inducing potency and selective pro-apoptotic action.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (10)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (10.00)18.7374
1990's3 (30.00)18.2507
2000's1 (10.00)29.6817
2010's5 (50.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 31.16

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index31.16 (24.57)
Research Supply Index2.48 (2.92)
Research Growth Index4.94 (4.65)
Search Engine Demand Index47.92 (26.88)
Search Engine Supply Index2.74 (0.95)

This Compound (31.16)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other11 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]